Akebia Therapeutics
NEWS
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
Shares of Akebia Therapeutics are up more than 10 percent in premarket trading after the company announced it struck a merger agreement with Keryx Biopharmaceuticals, Inc. to create a company expected to be a leader in the development of renal disease therapies.
Akebia Therapeutics, a kidney disease company, announced plans to offer and sell about $85 million of its common stock in an underwritten public offering.
In an overall good year for pharma and biotech sectors, there have been some standouts.
JOBS
IN THE PRESS